TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

After questioning Terawan's vaccine, drug regulator faces political pressure

The Jakarta Post Image
Elderly people await pre-COVID-19 vaccination screenings at a community health center in Palmerah, West Jakarta, on Feb 25.(JP/Ardila Syakriah)
Ardila Syakriah
PREMIUM
Jakarta   ●   Thu, March 11, 2021

After questioning the data and rigor of the initial trials of a candidate vaccine backed by former health minister Terawan Agus Putranto, the Food and Drug Monitoring Agency (BPOM) has faced increased political pressure to allow the controversial jab to enter mid-stage trials.

Terawan began his efforts to develop the vaccine, called Nusantara, while he was in office last year. The Health Ministry was touted as a sponsor, alongside American biotechnology firm AIVITA Biomedical and Gresik-based pharmaceutical company Rama Emerald Multi Sukses in East Java.

The candidate vaccine employs a unique mechanism. It is tailored to each recipient through the use of their own antigen-presenting dendritic cells. Such cells have been used in cancer therapies.

“Since 2015, I have been personally developing dendritic cell-based vaccines at the Cell Cure Center of t...

to Read Full Story

SUBSCRIBE NOW

Starting from IDR 55,000/month

  • Unlimited access to our content on web and app
  • No advertising, no interruption
  • A bonus subscription to share
  • Bookmark and night mode functions on app
  • Subscription to our newsletters

We accept